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SUMMARY
Objective: This study aimed to examine drug packaging and labeling, identifying sim-
ilarities among them that may lead to medication errors, which may occur by unin-
tentional substitution, in different sectors of the pharmacy of a university hospital in 
northeastern Brazil. Methods: Cross-sectional observational study, which included 
300 pharmaceutical presentations (150 pairs) that were photographed from May to De-
cember 2010. Concordance analysis of data related to the pictures of possibly similar 
packaging and labels was validated using the Kappa index. Results: Of all drugs eval-
uated (n = 150), about 43% of “possibly similar drugs” were in the central pharmacy 
(n = 65) and were related to small-volume parenteral solutions. The strength of interob-
server agreement in the category “very similar to each other” was considered “satisfac-
tory” (Kappa = 0584) in 90.66% of the drugs evaluated (n = 136). The overall Kappa 
analysis of the study was 0.488. Variables with statistical significance were: “same color 
label or packaging”, with the respective percentages for both primary and secondary 
packaging (52%-44%), p = 0.028; the variable “same color of drug presentation” ob-
tained similar values  and statistical significance to the previous variable; for the variable 
“same arrangement of words”, the values  found for both packages were close to 50%, 
p = 0.001; and for the variable “same color of the words”, the percentages were: (50.7% - 44%) 
(p = 0.008). Conclusion: Our results indicate similarities related to the labeling of drugs 
with potential for errors, especially in dispensing, storage, and administration if preven-
tive measures are not adopted.  
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INTRODUCTION
Generally, the term “patient safety” involves preventing 
errors in care and the elimination of damage caused to pa-
tients by such errors. Conceptually, healthcare errors are 
the result of nonintentional actions caused by some prob-
lem or failure while caring for the patient1. In this con-
text, the National Health Surveillance Agency (ANVISA) 
has defined “medication error” as preventable event that 
can actually or potentially lead to inappropriate use of 
medication, which may or may not harm the patient. It 
may be related to professional practice, the product used, 
procedure, poor communication on prescription, labels, 
packaging, preparation, dispensing, distribution, and 
monitoring and may be the result of actions by any mem-
ber of staff at any point in the care process1,2.  
Many paradigms are challenged when it comes to 
medication errors. Health professionals usually associate 
errors in their activities with shame, loss of prestige, and 
fear of punishment2. To contribute to the reduction of er-
rors, one needs constant, careful and attentive analysis 
by health institutions of errors that effectively occur. In 
recent years, much has been said about the investigation 
of medication errors, as it is of fundamental importance 
to promote the reliability of the medication system and 
patient safety3.  
Carvalho et al.4 reported that error prevention should 
be based on actual search for causes, which oen include 
errors in service organization and implementation sys-
tems. Moreover, errors must be accepted as evidence of 
system failure and seen as an opportunity to review the 
process and improve the care provided to patients, as 
emphasized in the celebrated article Éviter l’évitable. Tirer 
parti des erreurs pour mieux soigner, which is translated 
into English as “Preventing the preventable. Taking ad-
vantage of errors to improve care”5,6. 
One of the explanations for the large number of er-
rors observed in the hospital environment is exactly the 
lack of mechanisms to reduce its occurrence or to pre-
vent the error before it reaches the final consumer (the 
patient). That is, one works with the premise that 
the health professional does not make mistakes and 
therefore mechanisms for error prevention and correc-
tion are not created 4.
In the hospital environment, the pharmacy is re-
sponsible for the safe and effective use of drugs and must 
comply with the essential role of integrating the process-
es of drug prescription, dispensing, and administration 
and must have policies and procedures to prevent them. 
In this sense, the error rate measurement is considered 
one of the best indicators of quality of a drug distribu-
tion system in hospitals and is used to evaluate the safety 
of these systems7,8 According to Silotti et al.9, together 
with the multidisciplinary team, the pharmacist active 
participation is an important strategy for error preven-
tion, as he operates during the phases of selection, pro-
curement, storage, distribution, dispensing, and moni-
toring, identifying the potential risks.
One of the points described as a trigger for drug dis-
pensing and administration errors is the similarity of drug 
names and packaging. The Brazilian market still admits 
the non-compliance regarding the similarity of packaging 
and labels, which are almost mistakable, so that in hos-
pitals in Brazil there are countless similar types of pack-
aging and labels, leading professionals involved in drug 
dispensing and administration to unintentionally switch 
them. Merino et al.10 consider in their study that for the 
safety of packaging and labels of similar drugs, it would be 
necessary, whenever possible, to avoid purchasing medica-
tions with similar appearance, and also incorporate other 
mechanisms to prevent errors, such as local adequate stor-
age and even differentiated drug labeling. 
Errors occur as a consequence of these similarities, 
which could be prevented with simple actions by the 
pharmaceutical industry. This problem has not been ad-
dressed by the Brazilian pharmaceutical industry, in order 
to promote a global action regarding the standardization 
of packaging and labeling of drugs, very oen ignoring the 
important role it should play in improving the safe use of 
medications. Unfortunately, to date, there is no Brazilian 
law regulating the standardization of packaging and la-
bels focused on similarity prevention, which would force 
the pharmaceutical companies to make changes, testing 
packaging and labels to maintain an appropriate standard 
in the various families of pharmaceutical drugs11. Even 
aer reports of errors associated with similar names and 
packaging, the Brazilian studies assessing the extent of the 
problem are very incipient.  
Consequently, this study aimed to assess the packag-
ing and labeling of medications, identifying similarities 
between them that may lead to medication errors by unin-
tentional substitution.
 
METHODS 
This is a cross-sectional observational study, carried out 
between May and December 2010, in a university hospi-
tal in northeastern Brazil, connected to the network of 
Anvisa Sentinel Hospitals. Data were collected using a 
sampling of photographic images, achieved through the 
calculation for cross-sectional studies, with a prevalence 
of 33% (percentage with which the phenomenon occurs, 
according to previous publications), with a sampling er-
ror of 5% (0.05 = level of significance), and a confidence 
level of 95% (expressed as number of standard deviation 
1.96). We added 10% to the sample size due to the chance 
of losses and refusals, resulting in 300 pharmaceutical 
presentations, in 150 pairs.
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We monitored a stored drug ow in the order estab-
lished by simple randomization to define the areas of the 
hospital pharmacy to be visited and defined in the follow-
ing sequence: central pharmaceutical supply (CPS), on-
cology unit, central pharmacy, surgical department phar-
macy, fractionation unit, and outpatient clinic pharmacy.  
The data collection tool and methodology to be used 
have been validated in a pilot study. The photographs 
were analyzed using a fully structured checklist type 
form, with dichotomous variables, which was filled out 
by direct observation of the available drugs in hospital 
sectors. Similarity cases were entered on database and 
characterized based on international references, such as 
the National Coordinating Council for Medication Error 
Reporting and Prevention (NCCMERP), Taxonomy of 
Medication Errors Now Available,12 and Resolutions of 
the Collegiate Board (RDC) of the National Health Sur-
veillance Agency – Anvisa (RDC N. 333/2003, 09/2001 
and 71/2009)13-15.
All trademarks and pharmaceutical preparations 
available at the hospital during the collection were in-
cluded in the 150 pairs of drugs studied. The variables 
recorded included dosage forms and presentations, types 
of packaging, name, color, design, dosage, and pharma-
cological group according to the Anatomic Therapeutic 
Chemical Classification (ATC )16, whereas suppliers and 
potential risk [high-alert medications (HAM)] were also 
verified, as well as controlled medications.  
When analyzing the type of medication, we consid-
ered the names specified by Anvisa17 for reference, gener-
ic, and similar drugs in which, according to the legal defi-
nition, the reference drug is the innovative one registered 
with the federal agency responsible for health surveil-
lance and marketed in the country and whose e cacy, 
safety, and quality have been scientifically proven to the 
competent federal agency upon registration. The e cacy 
and safety of the reference drug have been demonstrated 
through clinical study presentation. Generic drug is one 
that contains the same active ingredient at the same dose 
and dosage form. It is administered by the same route 
and has the same safety level and therapeutic indication 
of the reference drug in the country; thus, reference and 
generic drugs are interchangeable. 
As for similar drugs, they are those that contain the 
same active ingredient or ingredients, have the same 
concentration, dosage form, route of administration, 
dose and therapeutic indication, and are equivalent to 
the drug registered at the federal agency responsible for 
health surveillance and may only differ in characteristics 
related to size and shape of the product, shelf life, packag-
ing, labeling, excipients and vehicle, and must always be 
identified by trade name or brand. Generic and similar 
drugs can be considered “copies” of the reference product. 
For registration of both generic and similar drugs, the 
submission of relative bioavailability and pharmaceuti-
cal equivalence studies are mandatory. The study also 
included medication with packaging from the Ministry 
of Health.
Association analysis was carried out using the Sta-
tistical Package for Social Sciences for Windows (SPSS), 
version 16.0. Statistical tests for significant associations 
were based on Pearson’s chi-square (2) or Fisher’s exact 
test, considered to be statistically significant when < 5%. 
Agreement was measured using Kappa statistics 
through the one-tailed test, verifying if there was agree- 
ment between the classifications, and the level of 
agreement of these hypotheses was reproduced from the 
null hypothesis H0: k = 0. 
Statistical significance of the correlation was assessed 
by derivation and obtaining the p-value, with statistical 
significance set at p < 0.05. The Kappa index and 95% 
confidence intervals were also obtained. For interpreta-
tion of aggregation for the Kappa value, we adopted the 
criterion of Landis and Koch18, being considered as per-
fect agreement a kappa value of 1.
The analysis of inter-observer agreement regarding 
the sample volume of packaging and label photos of pos-
sibly similar drugs was presented to three independent 
observers with experience in nursing and pharmacy, as 
follows: a female nurse (observer 1); a female pharmacist 
(observer 2); a male nurse (observer 3). They assessed, at 
different times, with a minimum interval of one week for 
each observer, a situation in which they compared labels 
and packaging of different drugs through pictures. The 
images were taken using a Samsung camera model SL820 
IT/100 and identified through an alphanumeric code 
created specifically for the study, and inserted into the 
database in JPEG format, with 2048 x 1536 dimensions, 
and then randomly distributed to each observer. The ob-
servers, aer receiving the images, performed  the images 
classification using the following denomination: (1) very 
similar to each other, (2) somewhat similar to each other. 
and (3) there are no similarities. 
Data were submitted to statistical analysis by deter-
mining the inter-observer agreement, based on interpre-
tations of each case individually performed by observers. 
The inter-observer agreement was assessed by consider-
ing the single interpretation of each observer, thereby 
combining the three interpretations. Each observer re-
corded his/her assessment in an adequate form, while 
blinded for the assessment of the other observers. 
Following the decision of the Research Ethics Com-
mittee of the hospital where the study was developed, re-
port No. 039.05.10, the research project was deferred, as 
it did not involve human subjects, but statistical analysis 
of data from observers. 
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Figure 1 – Drug distribution regarding drug classes involved 
in the process of assessment of similarity between drug 
packaging and labels. According to ATC classiﬁcation  – 
Level II. Hospital Universitário, Fortaleza – CE, Brazil, 2010.
RESULTS 
Regarding the type of medication, the similar ones were 
the most frequently found (46%, n = 69) in the 150 pairs 
analyzed. The reference and generic drugs had values that 
were respectively 21.33% (n = 32) and 18% (n = 27); while 
medications with packaging from the Ministry of Health 
accounted for 14.67% (n = 22).
Figure 1 shows the prevalence of antimicrobials (anti-
infectious drugs), including nucleosides and nucleotides 
reverse-transcriptase inhibitors, among the 24 therapeu-
tic classes studied (28%, n = 42), followed by anesthetics 
(10.67%, n = 16) and antihypertensive drugs (6.67%, n = 10).
These medications were studied in different sectors of 
the hospital pharmacy, the central pharmacy accounting 
for the highest number of possibly similar drugs (43.33%, 
n = 65), followed by the outpatient clinic pharmacy 
(24.66%, n = 37) and the CPS (10.67%, n = 16). 
Similar proportions were observed for the surgical de-
partment pharmacy and the in fractionation unit (8.67%, 
n = 13). As for the oncology unit, the percentage was much 
lower (4%, n = 6). 
When analyzing the criterion “similarities”, Table 1 
shows three categories, namely: “very similar to each oth-
er”, “somewhat similar to each other”, and “no similarities.” 
The strength of agreement ranged from poor to moder-
ate (close to an agreement considered to be “good”; Kappa 
from 0.379 to 0.584). As for the “very similar” category, the 
inter-observer agreement was considered “satisfactory” 
(Kappa = 0.584) in 90.66% (n = 136) of drugs evaluated. In 
the category “somewhat similar to each other,” the agree-
ment was considered “weak” (Kappa = 0.379).
In the category “no similarities,” the agreement was 
considered “moderate” (Kappa = 0.433). The overall Kap-
pa analysis throughout the study was 0.488.
The results obtained in the analysis of similarities re-
garding drug packaging and labeling were stratified ac-
cording to the printed data, design, procurement, and po-
tential hazards associated with the drugs (Table 2). In the 
category “information printed on the labels”, the variable 
“label” or “packaging of the same color” were identified in 
primary and secondary packaging of the drugs showing 
the following percentages 52% (n = 78) and 44 % (n = 66), 
respectively, (p = 0.028). For the other items, we observed 
the “same disposition of words” for both primary (46.7%, 
n = 70) and secondary packaging (44%, n = 66), with re-
sults that were also statistically significant (p = 0.001).  
When analyzing “the same color of the words”, a per-
centage of 50.7% (n = 76) was obtained for the primary 
and 44% (n = 66) (p = 0.008) for the secondary packaging.
Also in the category data printed on the labels, we 
analyzed the description of names and pronunciations, 
with the following results: the same percentage of 17.30% 
(n = 26) was found for similar names in the primary and 
secondary packaging. Moreover, when evaluating the same 
category, it was observed that the drugs with the same pro-
nunciation had a value of 18% (n = 27) for the primary 
packaging and 19.30% (n = 29) for secondary packaging; 
no statistically significant results were found for these two 
variables. 
In the “design characteristics” category, the variables 
investigated were “same size” and “same color”. The fol-
lowing variables were found for “size” [primary (48%, 
n = 72) and secondary packaging (37.30%, n = 56) 
(p = 0,531)] and “same color of the pharmaceutical prepa-
ration” [primary (52%, n = 78) and secondary packaging 
(44%, n = 66) (p = 0.028)].  
Other aspects of the pharmaceutical preparation were 
analyzed, such as material characteristics and data print-
ed on the label or glass vial packaging, which accounted 
for 34% (n = 51) of the total dosage forms in the study. In 
this sample (n = 51), the following variables were evalu-
ated: whether the vials were made of plastic or glass, if 
they had self-adhesive labels, or if they were printed. 
The plastic vials showed values  close to 30% (27.45%, 
n = 14/51), whereas glass ones were prevalent, with 
more than 70% (72.55%, n = 37/51). As for identifica-
tion, it was examined whether the vials were character-
ized with self-adhesive labels or if they were printed. For 
the self-adhesive labels, the percentage found was 58.82% 
(n = 30/51), while for vials with printed labels it was 
41.18% (n = 21/51).
Regarding HAM comparative analysis, the primary 
and secondary packaging potential to cause damage was 
26% and 14%, respectively, with p = 0.05.
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DISCUSSION
Medications have a prominent place in health care and 
disease treatment. The alternative to achieve a cure is, for 
many individuals, the use of drugs19,20.
Currently, more than 80% of patients who seek health 
services receive prescription drugs. There is a large num-
ber of prescription medications for hospitalized patients. 
Cassiani et al.20 reported that patients received up to 17 
medications per day during hospitalization, and nearly 
sixteen percent of the study participants were prescribed 
more than 10 types of drugs. 
Our study describes the possibility of potential error 
related to medications with similar labeling, which con-
stitutes an event or situation that could have resulted in 
accident, injury, or illness, but by sheer luck was not iden-
tified or nothing happened. According to Leape et al.21, er-
rors occur in all phases of the medication system: 39% of 
errors occur at the drug prescription, 12% at transcrip-
tion, 11% at dispensing, and 38% during administration. 
Nurses and pharmacists intercept 86% of medication er-
rors related to prescription, transcription, and dispensing 
errors, while only 2% are intercepted by the patients. 
Our study was developed at the pharmacy of a univer-
sity hospital and showed that the most “possibly similar” 
drugs were in the central pharmacy (43.33%, n = 65/150). 
It should be also noted that many of these drugs (51.33%, 
n = 77/150) were small-volume parenteral solutions (vials, 
closed-system bags), with higher risks for adverse events 
in drug administration. 
Potential risk for medication errors exists in differ-
ent sectors; however, the central pharmacy or dispens-
ing sector is responsible for the quantity of drugs that are 
dispensed to the several inpatient units, which extends 
this risk to other phases of the medication system and is 
aggravated by the number of patients being cared for by 
the multidisciplinary team22. 
To ensure the prevention of medication errors, all 
health professionals should be involved in this system. 
Pharmacists are essential to ensure the rational and safe 
use of medications, as well as to warn about medica-
tion errors and how to prevent them. Most errors can 
be avoided if there is a distribution system that allows 
focusing on the process of preparing doses in the phar-
macy service and more participation of the pharmacist 
by checking the prescription before dispensing it. 
On the other hand, an effective interaction between 
the nursing service and the pharmacy service is critical, 
as many of the errors that occur during the dispensing 
process can be prevented at the time of drug administra-
tion by the nursing staff.
A multicenter study involving four hospitals in differ-
ent regions of the country identified high rates of errors in 
the preparation and administration of medications. The 
authors suggest that to improve safety in drug delivery 
systems it is necessary to adopt a change in institutional 
culture in order to achieve concrete improvements23. 
Considering this scenario, it is interesting to discuss 
the events occurred in the hospital environment and to 
Table 1 – Results of the Kappa analysis according to the level of agreement classiﬁcation at Hospital Universitário, Fortaleza  – 
CE, Brazil, 2010
The observers performed, at different times, the inter-observer analysis of agreement and evaluated a situation in which they compared 
packaging and labels through pictures (n = 150 pairs), according to the following classiﬁcation: very similar; little similar to each other; 
and no similarities. The interpretation of aggregation for the value of Kappa adopted the criteria of Landis and Koch18, with a Kappa 
value = 1 being considered as perfect agreement and statistical signiﬁcance set at p < 0.05. CI, conﬁdence interval.
Not similar to each other
Analysis n % 95% CI p
Kappa 
index

Observer 1 4 2.67
 
 
0.341-0.526
 
 
< 0.001
 
 
0.433
150
Observer 2 3 2.00 150
Observer 3 2 1.33 150
Overall Kappa 150 100 0.412-0.564 < 0.001 0.488 150
Analysis n % 95% CI p
Kappa 
index
n % 95% CI p
Kappa 
index
Total
Observer 1 143 95.33
0.492-0.677 < 0.001 0.584
3 2.00
0.286-0.471 < 0.001 0.379
146
Observer 2 138 92.00 9 6.00 147
Observer 3 138 92.00 10 6.67 148
   Very similar to each other Little similar to each other
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suggest changes in the medication circuit in hospitals, 
including: drug dispensing, administration, and storage, 
which are considered critical and are highly intercon-
nected.
Thus, two approaches to human errors that occurred 
with identical drugs are described below: bottles of Vase-
line and saline solution were identical and the names of 
the medications in the label were written in the same col-
or, and were similar regarding the size, shape and color of 
the ip-top cover, causing the death of a child. The nurse 
aid told the police she was induced into error because the 
bottles were in the same cabinet (local). Aer the incident, 
the hospital responsible for the occurrence changed drug 
labeling procedures24.  
A total of 150 pairs of pictures were analyzed, observing primary and secondary packaging concerning: data printed on drug labels; description of 
names, pronunciations and procurements; design features; and high-alert medications (HAM). * Pearson’s chi-square test or Fisher’s exact test with 
signiﬁcance set at p < 0.05.  
Table 2 – Distribution of types of similarities stratiﬁed by printed data and design of drug labels analyzed in Hospital 
Universitário, Fortaleza – CE, Brazil, 2010
Data printed on the  medication labels
Labeling Same color of label or packaging Same disposition of printed words Same color of words
Primary packaging
n = 84/150 % p n = 84/150 % p n = 84/150 % p
78 52
0.028
70 46.7
0.001
76 50.7
0.008Secondary 
packaging
n = 66/150 % n = 66/150 % n = 66/150 %
66 44 66 44 66 44
Description of names, pronunciations and procurements
Labeling Similar names Same pronunciation Same manufacturer
Primary packaging
n = 84/150 % p n = 84/150 % p n = 84/150 % p
26 17.3
0.183
27 18
0.095
49 32.7
0.001Secondary 
packaging
n = 66/150 % n = 66/150 % n = 66/150 %
26 17.3 29 19.3 62 41.3
Characteristics of design and information on the  package label
Dosage form Plastic Glass Auto-adhesive labels Printed
Glass vials
n = 51/150 % n = 51/150 % n = 51/150 % n = 51/150 %
14 27.45 37 72.55 30 58.82 21 41.18
Characteristics of design
Labeling Same size Same color
Primary 
packaging
n = 84/150 % p n = 84/150 % p
72 48
0.531
78 52
0.028Secondary 
packaging
n = 66/150 % n = 66/150 %
56 37.3 66 44
Labeling High-alert medications (HAM)
Primary 
packaging
n = 84/150 % p
39 26
0.05Secondary 
packaging
n = 66/150 %
21 14
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Another case of a potentially dangerous drug that 
caused cardiac arrest happened when potassium chloride 
was wrongly exchanged, due to the similarity with dis-
tilled water vials and for being stored in the same place, 
causing the death of a 3-year-old child due to accidental 
exchange of distilled water by chloride potassium. The 
error occurred while the nurse prepared an injection of 
sodium ampicillin and hydrocortisone to treat the pa-
tient for an infection (pneumonia). Because the drug for-
mulation is in powder form, it needed to be diluted with 
distilled water or saline solution. The nursing assistant 
diluted the antibiotic with potassium chloride. Blood 
samples were collected from the child’s body, and the test 
result was positive for high levels of potassium25.  
Most institutions blame the error on the individual, 
without taking into account the systemic causes and 
weaknesses in the medication system26. Thus, we em-
phasize the importance of guidelines or recommenda-
tions for improving patient safety in cooperation with 
the o cial organs of the public health system in Brazil, 
regulatory agencies, and public or private healthcare es-
tablishments, with the active participation of health pro-
fessionals to facilitate the development of strategies to 
minimize these errors. 
Considering this perspective, it is important to mea-
sure possible errors that may happen when you have 
drugs with similar packaging and labels, making it ad-
missible to evaluate and ensure that the information 
abstracted from this study do not constitute only mere 
observations by the researcher. Thus, we used the Kappa 
index to evaluate and ensure that the product obtained 
by processing the digital images would be analyzed qual-
itatively and quantitatively, establishing the agreement 
among professionals in order to discuss the real risk of 
having drugs in the hospital environment with similar 
packaging and labels that could induce health profession-
als to medication errors. 
When we analyzed the criterion “very similar to each 
other,” the strength of inter-observer agreement was con-
sidered “satisfactory” (Kappa = 0.584) among the drugs 
evaluated. Whereas a perfect correlation is 1.00, there 
was a “regular” agreement index for the overall Kappa 
analysis (0.488). 
Considering that there was an agreement among 
professionals, we analyzed several items that pointed to 
possible similarities between drug packaging and label-
ing, including: data printed on the labels of medications, 
description of names, pronunciations, procurements, de-
sign characteristics, and the potential hazards. 
In the category of data printed on labels, our study 
tried to assess the inuence of some variables that could 
be implicated in potential medication errors caused by 
the misunderstanding of drug names. Analyzing the 
description of names and pronunciations for primary 
and secondary packaging, no statistical significance was 
found for both similar names and same pronunciation, 
and lower values  than those identified by Hoffman et al.27 
and Berman28 were found, where similar packaging as 
well as names with orthographic or phonological similar-
ity (looks like or sounds like) showed error values  of 25 
to 29%, as pharmacists and nurses can be led to uninten-
tional drug exchanges resulting in damage to the patient 
and even death.  
Still, according to Hoffman et al.27, name misunder-
standing is constantly associated with errors, although 
there is no apparent reason for that, as the ideal procedure 
is to read the labels at least three times before administer-
ing the medication. Even with regulations established by 
Anvisa with RDC N. 333 of 11/19/0313, which established 
rules to prevent any similarities between name brands in 
the market, there are still similar brands that have not 
been reviewed by the regulatory agency, which grants 
registration of similar or even identical names to differ-
ent medicinal substances. 
The analysis of Berman’s data28 showed that similari-
ties in drug names have oen been ignored, generating 
names with spelling or phonological similarity that ac-
counted for approximately 25% of medication errors, in-
creasing the risk of adverse events to patients. Moreover, 
similar packaging and labeling of drugs accounted for 
33% of medication errors, lower than the results found 
in our study.
Other aspects that were researched and discussed 
concerned the characteristics of the material and data 
printed on labels or packaging of glass vials, which ac-
counted for 34% of all pharmaceutical presentations in 
the study, and among several examples of causes of medi-
cation errors for situations of extreme risk, we could 
mention the wrong preparation of injectable drugs. The 
glass vials were also found in the hospital environment 
more oen than plastic ones and, in relation to identifica-
tion, vials with self-adhesive labels predominated. 
Taking into account the context of drug delivery sys-
tems in health institutions, the segment of self-adhesive 
labels on vials of injectable medicines is one of the most 
promising for drug differentiation (diversity of colors, 
graphics), capable of being printed. Additionally, they 
provide versatility to the production line and also to 
other processes outside the production line (e.g., hospi-
tals) with well-structured logistics departments equipped 
with technology to capture and process data. This label-
ing system allows the possibility of including barcodes 
in vials, facilitating inventory control, identification, and 
assessment at the time of use and tracking of units, which 
is not observed in the traditional recording with the glass 
printing method, which mostly bear similarities among 
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the drugs marketed in Brazil. The concept of patient safe-
ty in hospitals is resulting in some progress, including the 
use of drugs with self-adhesive labels, which improves 
drug identification29. 
Another interesting aspect is that some of the drugs 
studied were the so-called high-alert medications or 
high-risk medications, which represented for the pri-
mary packaging a percentage of 26%. This was expected 
as the dosage form of glass vials accounted for 34% of 
all pharmaceutical presentations in the study. For the 
secondary packaging, a smaller percentage of 14% was 
found with p = 0.05, close to statistical significance. Ac-
cording to Rosa et al.30, errors that occur with these drugs 
are not the most usual ones, but when they do occur, they 
have the highest severity and may lead to permanent in-
jury or be fatal. 
Still according to Rosa et al.30, it was observed that 
over 90% of errors with HAM were concentrated on 11 
drugs, namely heparin, fentanyl, midazolam, nalbuphine, 
pancuronium, dopamine, potassium chloride, tramadol, 
epinephrine, morphine, and pethidine. Corroborating 
our research, Figure 1 shows that of the 24 therapeutic 
classes analyzed, anesthetics were the second most com-
monly found (10.67%), followed by analgesics and anti-
inammatory drugs. Electrolytes also had a considerable 
percentage (5.33%). As for antithrombotic agents, a per-
centage of 3.33% was found among the studied drugs. 
When the research was related to the “type of medica-
tion and procurements” criterion, similar drugs were the 
most commonly found, what was expected for a teaching 
hospital that carries out procurement through a bidding 
process. The purchasing of medications for both primary 
and secondary packaging showed percentages near or 
equal to 40%, with statistical significance of p = 0.001 
for the variable “same manufacturer”, suggesting that the 
similarity in labels and packaging is also related to the 
production of different drugs by the same manufacturer, 
which generally uses the same artwork on the packaging 
for different products, without considering the peculiari-
ties in drug labeling. 
CONCLUSION
Our results indicate similarities related to drug labeling 
with potential for errors, especially in dispensing, stor-
age, and administration if preventive measures are not 
adopted. 
We emphasize the importance of guidelines and rec-
ommendations for improving patient safety with the col-
laboration of the Brazilian healthcare system, regulatory 
agencies, and public or private health establishments, as 
well as the active participation of health professionals, 
thus facilitating the development of strategies to mini-
mize errors that may be harmful to patients. 
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